Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kite, A Gilead Company
With
Arcellx, Inc.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsed and refractory Multiple Myeloma treated with at least 3 prior regimens of system therapy including Proteosome Inhibitor (PI), immunomodulatory drugs (IMiD), and anti-CD38 antibody (CD38mab); or has "triple-refractory" disease
Documented measurable disease
Adequate organ function
Life expectancy \> 12 weeks, Eastern Cooperative Group Performance Status 0-1
You may not be if
Plasma Cell Leukemia or History of Plasma Cell Leukemia
Patients with a history of severe hypersensitivity to DMSO should be excluded
Contraindication to fludarabine or cyclophosphamide
Severe uncontrolled intercurrent illness (e.g., infection) or laboratory abnormalities
Active central nervous system disease involvement by malignancy or active CNS pathology